Recall Enforment Report D-0099-2026

Recall Details

Drug Recall Enforcement Report Class II voluntary initiated by Samsung Bioepis Co., Ltd., originally initiated on 10-10-2025 for the product HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01. The product was recalled due to lack of assurance of sterility.. The product was distributed in Distributed Only To One Warehouse In Nj. With No Further Distribution and the recall is currently ongoing.

Field Name Field Value
Event ID 97710 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number D-0099-2026 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern Distributed only to one warehouse in NJ. with no further distribution What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.
Reason For Recall Lack of Assurance of Sterility. What is the Reason for Recall?
Information describing how the product is defective.
Product Quantity 5,518 packs (11,036 Syringes) 2 syringes/carton) Product Quantity
The amount of product subject to recall.
Voluntary Mandated Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date 11-05-2025
Recall Initiation Date 10-10-2025 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.
Initial Firm Notification Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type Drugs
Recalling Firm Samsung Bioepis Co., Ltd.
Code Info Lot: F2505017, Expiry: 24-Jan-2027 Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages 78206-183-99; 78206-183-01; 78206-184-99; 78206-184-01; 78206-185-99; 78206-185-01; 78206-186-99; 78206-186-01; 78206-187-99; 78206-187-01; 78206-187-58; 78206-187-59
Status Ongoing

Recalled Products

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
78206-183Hadlima Adalimumab-bwwdSolutionSubcutaneousOrganon LlcHuman Prescription Drug
78206-184Hadlima Adalimumab-bwwdSolutionSubcutaneousOrganon LlcHuman Prescription Drug
78206-185Hadlima Adalimumab-bwwdSolutionSubcutaneousOrganon LlcHuman Prescription Drug
78206-186Hadlima Adalimumab-bwwdSolutionSubcutaneousOrganon LlcHuman Prescription Drug
78206-187Hadlima Adalimumab-bwwdSolutionSubcutaneousOrganon LlcHuman Prescription Drug